Azenta, Inc. (AZTA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$30.15-2.17%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Azenta focuses on improving its Multiomics business. Revenue was $64 million. Free cash flow is expected near 12% next quarter. The company aims to grow revenue about 4% next year.
Azenta missed earnings twice recently. Multiomics revenue is flat at $64 million. Analysts cut earnings estimates sharply. Profit margins remain thin and cash flow weak.
The price is about 11% above our fair value near $23. Analysts expect about 4% revenue growth. Our view is cautious due to weak earnings and flat revenue.
Breaks if: FCF margin falls below 10% next quarter
Breaks if: YoY revenue growth falls below 0% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
AZTA represents a turnaround investment with a focus on transforming its Multiomics business. The current thesis state is cautious, as recent financial performance has been weak, but the sector backdrop offers potential support.
The market currently assumes a high valuation for AZTA, which is considered unjustified given its loss-making status and recent mixed results. There is an expectations gap, indicating that the market may not fully account for the risks and challenges ahead.
Fundamentals may show limited organic growth progress, as management has revised down revenue growth expectations. Recent results indicate mixed performance in key areas, with a cautious outlook reflecting the company's challenges.
The thesis hinges on management's ability to execute its transformation strategy and the broader healthcare sector's performance. Key triggers include potential guidance cuts and the impact of economic conditions on cyclical names like AZTA.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The CEO transition raises concerns about operational discipline. This change threatens the company's stability and future performance.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on strengthening commercial execution, optimizing operating footprint, and improving productivity in Multiomics.
Stated as a priority in 3 of last 3 quarters. Multiomics revenue showed mixed performance: $67M in 2026-Q1 (+1% YoY), $64M in 2026-Q2 (flat YoY), and $73M in 2026-Q3 (+10% YoY). Management emphasizes transformation with focus on commercial execution and productivity. The trajectory shows mixed progress with recent improvement in 2026-Q3, consistent with management's ongoing focus.
“Our priority is the transformation of our Multiomics business, with a focus on strengthening commercial execution, optimizing our operating footprint, and improving productivity.”
“In 2026, our priority is the transformation of our Multiomics business, focusing on strengthening commercial execution and improving productivity.”
“We remain committed to our fiscal 2026 objectives and our expectation for a stronger second half of the year, supported by our ongoing execution initiatives.”
Breaks if: YoY revenue growth falls below 3% next year
Over the next 1 to 3 years, AZTA's performance will depend on its operational execution and external market factors. Not investment advice.